pharmaphorum

JUNE 27, 2022

per share for Cambridge, Massachusetts-based Epizyme – valuing the US company at around $247 million – and is also promising a further contingent value right (CVR) payment of up to $1 per share if Tazverik (tazemetostat) achieves certain development and sales targets. Ipsen is offering $1.45 Ipsen’s CVR offer includes $0.30

Biopharma 110

Biopharma Sales Prescription FDA 110

PM360

SEPTEMBER 21, 2023

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

PM360

APRIL 7, 2023

This is especially significant for manufacturers of high-cost specialty drugs, who will now face a recurring additional 20% charge on virtually every prescription fill. Given the volume of 340B sales (13% of total U.S. Quality and value measurements commonly used outside of the U.S. The 340B battle will rage on.

Manufacturing 97

Manufacturing Insurance Marketing Government 97

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Technology

JANUARY 16, 2023

The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. The legislation contains several provisions to lower prescription drug costs, including allowing Medicare to negotiate the cost of selected medicines.

Pharma 64

Pharma Pharmaceutical Manufacturing Marketing 64

Pharmaceutical Technology

JANUARY 16, 2023

The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. The legislation contains several provisions to lower prescription drug costs, including allowing Medicare to negotiate the cost of selected medicines.

Pharma 52

Pharma Pharmaceutical Manufacturing Marketing 52